Results 51 to 60 of about 3,123 (163)

Methicillin‐resistant Staphylococcus aureus bloodstream infections in the Northern Territory of Australia 2017–2022

Internal Medicine Journal, Volume 56, Issue 7, Page 1200-1208, July 2026.
ABSTRACT Background Methicillin‐resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) cause significant morbidity and mortality. In Australia's Northern Territory (NT), MRSA BSI prevalence is disproportionately high. Vancomycin remains standard therapy despite toxicity and complex monitoring requirements.
Sara Davison, Aliya Bryce, Duncan Campbell, Robert Baird, Thomas Ewin, Shahid Ullah, Sonja Janson, Danny Tsai   +7 more
wiley   +1 more source

Dalbavancin in clinical practice: a particular place for the elderly?

, 2022
International audienceWe investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old.
Le Maréchal, Marion, Wackenheim, Chloé, Pluchart, Hélène, Gavazzi, Gaëtan, Caspar, Yvan, Pavese, Patricia, Blanc, Myriam   +6 more
core   +1 more source

Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections – an observational, retrospective review

Therapeutic Advances in Infectious Disease
Background: Treatment of invasive gram-positive infections in complex patient populations is challenging. Dalbavancin, approved for skin and soft tissue infections, offers advantages in this setting due to its long half-life and infrequent dosing ...
Hongkai Bao, Rita Igwilo-Alaneme, Fnu Sonia, Kelsie Cowman, Mani Kahn, Priya Nori   +5 more
doaj   +1 more source

Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic

, 2008
The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection.
Chen, Anne Y., Billeter, Marianne, Dalovisio, Joseph R., Kurukularatne, Changa, Zervos, Marcus J.   +4 more
core   +1 more source

Correction to: A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing [PDF]

, 2022
Introduction: We previously demonstrated the efficacy of a frozen dalbavancin–heparin (DH) lock solution against biofilms of staphylococci. However, as enterococci also commonly cause catheter-related bloodstream infections (CRBSI), we assessed the ...
Pascual, Cristina, Muñoz, Patricia, Pérez-Granda, María J., Guembe, María, Díaz Navarro, Marta, Manzano, Irene, Guembe Ramírez, María, Hafian, Rama, Cercenado, Emilia, Pérez Granda, María Jesús, Pérez-Granda, María J, Cercenado Mansilla, Emilia, Rodríguez, Carmen, Díaz-Navarro, Marta   +13 more
core   +1 more source

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital

Microbiology Spectrum, 2023
Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs).
Richard Lueking, Wenjing Wei, Norman S. Mang, Jessica K. Ortwine, Jessica Meisner   +4 more
doaj   +1 more source

Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria

Angewandte Chemie, Volume 137, Issue 25, June 17, 2025.
A structurally distinct glycopeptide, saarvienin A, represents a new family of glycopeptide antibiotics consisting of five sugar/aminosugar units connected to a halogenated peptide core. Saarvienin A overcomes vancomycin resistance and shows strong activity against drug‐resistant Gram‐positive bacteria, in particular, high‐priority pathogens such as ...
Amninder Kaur, Jaime Felipe Guerrero‐Garzón, Sari Rasheed, Martin Zehl, Franziska Fries, Bernd Morgenstern, Sergey B. Zotchev, Rolf Müller   +7 more
wiley   +2 more sources

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections

Infectious Diseases and Therapy, 2019
Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections.
Jacqueline T. Bork, Emily L. Heil, Shanna Berry, Eurides Lopes, Rohini Davé, Bruce L. Gilliam, Anthony Amoroso   +6 more
doaj   +1 more source

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series

Annals of Clinical Microbiology and Antimicrobials, 2022
Background Dalbavancin is a semisynthetic antibiotic used as an alternative to vancomycin for skin infections and osteomyelitis. Its long half-life decreases length of hospitalizations.
Connor Evins, Harrison Lancaster, Amanda E. Schnee   +2 more
doaj   +1 more source

Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis

European Journal of Case Reports in Internal Medicine, 2023
Infective endocarditis is a relatively uncommon infection that requires a high index of suspicion, which can sometimes delay its diagnosis. It requires several weeks of intravenous antibiotics, which traditionally requires long hospital stays ...
Francisco Javier Teigell Muñoz, María Mateos-González, Elsa Bernal-Hertfelder, Ana Sánchez de Torre, María García-Ferrón, Carmen de Cáceres Velasco, Coralia Bueno Muiño   +6 more
doaj   +1 more source